null - FindTrial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2016-001828-56-FI

Enrollment

Unknown

Registered

2016-10-05

Start date

2016-12-09

Completion date

Unknown

Last updated

2017-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Problem gambling MedDRA version: 19.0 Level: LLT Classification code 10017657 Term: Gambling pathological System Organ Class: 100000004873

Interventions

Trade Name: NA Product Name: Naloxone hydrochloride 20mg/ml nasal spray Product Code: NA Pharmaceutical Form: Nasal spray, solution INN or Proposed INN: NALOXONE hydrochloride CAS Number: 51481-60-8 C

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: gambling pathological Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 15 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Pregnancy

Design outcomes

Primary

Measure	Time frame
Main Objective: Pilot study, no control group;Secondary Objective: NA;Primary end point(s): Time of gambling;Timepoint(s) of evaluation of this end point: 0 and 8 weeks	—

Secondary

Measure	Time frame
Secondary end point(s): NA;Timepoint(s) of evaluation of this end point: NA	—

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 20, 2026